Yosemite has launched as a new standalone entity, spinning off from Emerson Collective to form an independent investment firm based in San Francisco, focused on opportunities across the oncology ecosystem.
The new fund, which launches with a first close of $200M+, will employ both grantmaking and venture investing as a catalyst for scientific breakthroughs to become viable cancer patient solutions.
Composed of the Emerson Health team, led by Reed Jobs, Yosemite continues its investment strategy of providing grants to emerging research along with flexible funding for incubation and early-translation investments in therapeutics, diagnostics, and digital health.
The firm’s global network is designed to identify and fuel the most promising advances in treatment, technology, and standards of care.
Limited Partners include leading endowments, hospital systems and global family offices – such as The Rockefeller University, Memorial Sloan Kettering Cancer Center (MSK) and John Doerr. Emerson Collective will be a Limited Partner in Yosemite Fund I. Going forward, Yosemite will manage the Emerson Health legacy portfolio (ECI Health Funds) as an investment advisor.
FinSMEs
02/08/2023